An innovative strategy that uses a well-balanced monomeric peptide triagonist to target three metabolically related hormone receptors has been developed. This strategy seems to be the most effective pharmacological approach to reverse obesity and its metabolic comorbidities in rodents and could open new ways to tackle the dual burden of obesity and diabetes mellitus in humans.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Design of chimeric GLP-1A using oligomeric bile acids to utilize transporter-mediated endocytosis for oral delivery
Biomaterials Research Open Access 02 September 2023
-
An online tool for obesity intervention and public health
BMC Public Health Open Access 10 February 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Scheen, A. J. & Van Gaal, L. F. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol. 2, 911–922 (2014).
Finan, B. et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat. Med. 21, 27–36 (2015).
Sadry, S. A. & Drucker, D. J. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat. Rev. Endocrinol. 9, 425–433 (2013).
Neumiller, J. J. Incretin-based therapies. Med. Clin. North Am. 99, 107–129 (2015).
Campbell, J. E. & Drucker, D. J. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 17, 819–837 (2013).
Unger, R. H. & Cherrington, A. D. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J. Clin. Invest. 122, 4–12 (2012).
Lund, A., Bagger, J. I., Christensen, M., Knop, F. K. & Vilsbøll, T. Glucagon and type 2 diabetes: the return of the α cell. Curr. Diab. Rep. 14, 555 (2014).
Arafat, A. M. et al. Glucagon regulates orexin A secretion in humans and rodents. Diabetologia 57, 2108–2116 (2014).
Tan, T. M. et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes 62, 1131–1138 (2013).
Cegla, J. et al. Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake. Diabetes 63, 3711–3720 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.J.S. has received lecturer/advisor/investigator fees from AstraZeneca/BMS, Boehringer Ingelheim, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, NovoNordisk, Sanofi and Takeda. N.P. has received lecturer fees from Merck Sharp & Dohme and NovoNordisk.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Scheen, A., Paquot, N. A new paradigm for treating obesity and diabetes mellitus. Nat Rev Endocrinol 11, 196–198 (2015). https://doi.org/10.1038/nrendo.2015.3
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2015.3
This article is cited by
-
Design of chimeric GLP-1A using oligomeric bile acids to utilize transporter-mediated endocytosis for oral delivery
Biomaterials Research (2023)
-
An online tool for obesity intervention and public health
BMC Public Health (2015)